Table 1 Comparison of clinical characteristics and laboratory data of serum α-HBDH in LC patients
From: Prognostic value of serum α-HBDH levels in patients with lung cancer
Variables | Cases(n = 71) | α-HBDH > 220U/L (n = 44) | α-HBDH ≤ 220U/L (n = 27) | p value |
|---|---|---|---|---|
Clinical characteristic | ||||
Age (mean ± SD), years | 64.2 ± 11.0 | 63.5 ± 11.8 | 65.3 ± 10.1 | 0.699 |
Gender | ||||
Male | 52 (73%) | 28 (64%) | 24 (89%) | 0.021* |
Female | 19 (27%) | 16 (36%) | 3 (11%) | |
Smoking | 25 (35%) | 15 (34%) | 10 (37%) | 0.802 |
Metastasis | ||||
Liver | 8 (11%) | 6 (14%) | 2 (7%) | 0.640 |
Lymphnodes | 32 (45%) | 24 (55%) | 8 (30%) | 0.042* |
Kindey | 3 (4%) | 2 (5%) | 1 (4%) | 0.865 |
Brain | 13 (18%) | 10 (23%) | 3 (11%) | 0.222 |
Bone | 19 (27%) | 15 (34%) | 4 (15%) | 0.077 |
Staging (I + II/III + IV) | ||||
Low (I + II) | 12 (17%) | 5 (11%) | 7 (26%) | 0.096 |
High (III + IV) | 59 (83%) | 39 (89%) | 20 (74%) | |
Classification | ||||
Small-cell carcinoma | 17 (24%) | 12 (27%) | 5 (19%) | 0.109 |
Adenocarcinoma | 36 (51%) | 24 (55%) | 12 (44%) | |
Squamous cell carcinoma | 18 (25%) | 8 (18%) | 10 (37%) | |
Laboratory data | ||||
LDH, U/L | 284 ± 135 | 351 ± 132 | 176 ± 32 | < 0.001*** |
HCY, umol/L | 27.6 ± 52.5 | 31.6 ± 66.3 | 21.2 ± 9.2 | 0.644 |
FIB, g/L | 4.27 ± 1.51 | 4.34 ± 1.57 | 4.16 ± 1.42 | 0.603 |
CEA, ng/ml | 22.3 ± 20.6 | 25.3 ± 23.3 | 17.3 ± 14.3 | 0.079 |
AFP, IU/ml | 10.4 ± 6.3 | 11.2 ± 7.4 | 9.2 ± 3.5 | 0.141 |
TP, g/L | 66.2 ± 8.01 | 65.5 ± 7.54 | 67.2 ± 8.75 | 0.404 |
ALB, g/L | 36.1 ± 6.39 | 35.6 ± 5.79 | 36.9 ± 7.31 | 0.451 |
Ca, mmol/L | 2.26 ± 0.25 | 2.24 ± 0.20 | 2.31 ± 0.30 | 0.319 |
WBC, × 109/L | 8.57 ± 5.37 | 9.05 ± 6.10 | 7.78 ± 3.87 | 0.284 |
NLR | 8.30 ± 11.64 | 10.13 ± 14.14 | 5.32 ± 4.37 | 0.040* |
PLT, × 109/L | 226 ± 106 | 235 ± 113 | 211 ± 94 | 0.335 |